Kosteneffektivität von Transfusionsalternativen
Hämatologie
Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (öffnet neues Fenster)
Quelle: Blood Transfus 2020;18(2):106-16.
Indiziert: PubMed 31855149
DOI: 10.2450/2019.0248-19
https://www.ncbi.nlm.nih.gov/pubmed/31855149 (öffnet neues Fenster)
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (öffnet neues Fenster)
Quelle: Support Care Cancer 2013;21(2):485-93.
Indiziert: PubMed 22825456
DOI: 10.1007/s00520-012-1538-0
https://www.ncbi.nlm.nih.gov/pubmed/22825456 (öffnet neues Fenster)
Restrictive blood transfusion practices are associated with improved patient outcomes. (öffnet neues Fenster)
Quelle: Transfusion 2014;54(10 Pt 2):2753-9.
Indiziert: PubMed 24995770
DOI: 10.1111/trf.12723
https://www.ncbi.nlm.nih.gov/pubmed/24995770 (öffnet neues Fenster)
Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (öffnet neues Fenster)
Quelle: Clin Ther 2010;32(14):2478-93.
Indiziert: PubMed 21353116
DOI: 10.1016/j.clinthera.2011.01.011
https://www.ncbi.nlm.nih.gov/pubmed/21353116 (öffnet neues Fenster)
Recombinant activated factor VII use in critically ill infants with active hemorrhage. (öffnet neues Fenster)
Quelle: J Pediatr Surg 2008;43(12):2235-8.
Indiziert: PubMed 19040942
DOI: 10.1016/j.jpedsurg.2008.08.053
https://www.ncbi.nlm.nih.gov/pubmed/19040942 (öffnet neues Fenster)
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (öffnet neues Fenster)
Quelle: Blood Adv. 2022;6(3):785-92.
Indiziert: PubMed 34781363
DOI: 10.1182/bloodadvances.2021005627
https://pubmed.ncbi.nlm.nih.gov/34781363/ (öffnet neues Fenster)
Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (öffnet neues Fenster)
Quelle: Transfusion 2017;57(9):2189-96.
Indiziert: PubMed 28671296
DOI: 10.1111/trf.14191
https://www.ncbi.nlm.nih.gov/pubmed/28671296 (öffnet neues Fenster)
Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation. (öffnet neues Fenster)
Quelle: Biol Blood Marrow Transplant 2012;18(5):813-7.
Indiziert: PubMed 22080050
DOI: 10.1016/j.bbmt.2011.10.043
https://www.ncbi.nlm.nih.gov/pubmed/22080050 (öffnet neues Fenster)
The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. (öffnet neues Fenster)
Quelle: Transfusion 2019;59(11):3386-95.
Indiziert: PubMed 31664712
DOI: 10.1111/trf.15558
https://www.ncbi.nlm.nih.gov/pubmed/31664712 (öffnet neues Fenster)
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (öffnet neues Fenster)
Quelle: Transfusion 2015;55(12):2807-15.
Indiziert: PubMed 26264557
DOI: 10.1111/trf.13260
https://www.ncbi.nlm.nih.gov/pubmed/26264557 (öffnet neues Fenster)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (öffnet neues Fenster)
Quelle: Cancer 2013;119(1):107-14.
Indiziert: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (öffnet neues Fenster)
Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (öffnet neues Fenster)
Quelle: Cost Eff Resour Alloc 2013;11(1):16.
Indiziert: PubMed 23870502
DOI: 10.1186/1478-7547-11-16
https://www.ncbi.nlm.nih.gov/pubmed/23870502 (öffnet neues Fenster)
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (öffnet neues Fenster)
Quelle: Support Care Cancer 2012;20(1):159-65.
Indiziert: PubMed 21359879
DOI: 10.1007/s00520-010-1083-7
https://www.ncbi.nlm.nih.gov/pubmed/21359879 (öffnet neues Fenster)
Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. (öffnet neues Fenster)
Quelle: J Med Econ 2013;16(2):318-26.
Indiziert: PubMed 23216012
DOI: 10.3111/13696998.2012.756400
https://www.ncbi.nlm.nih.gov/pubmed/23216012 (öffnet neues Fenster)
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (öffnet neues Fenster)
Quelle: Hematology 2018;23(7):417-22.
Indiziert: PubMed 29157136
DOI: 10.1080/10245332.2017.1404262
https://www.ncbi.nlm.nih.gov/pubmed/29157136 (öffnet neues Fenster)
The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA). (öffnet neues Fenster)
Quelle: J Med Econ 2013;16(5):633-8.
Indiziert: PubMed 23425291
DOI: 10.3111/13696998.2013.778269
https://www.ncbi.nlm.nih.gov/pubmed/23425291 (öffnet neues Fenster)
Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (öffnet neues Fenster)
Quelle: Transfusion 2010;50(2):487-92.
Indiziert: PubMed 19804569
DOI: 10.1111/j.1537-2995.2009.02413.x
https://www.ncbi.nlm.nih.gov/pubmed/19804569 (öffnet neues Fenster)
Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (öffnet neues Fenster)
Quelle: Am J Hematol 2010;85(10):795-7.
Indiziert: PubMed 20645429
DOI: 10.1002/ajh.21772
https://www.ncbi.nlm.nih.gov/pubmed/20645429 (öffnet neues Fenster)
Increased hospital costs associated with red blood cell transfusion. (öffnet neues Fenster)
Quelle: Transfusion 2015;55(5):1082-9.
Indiziert: PubMed 25488623
DOI: 10.1111/trf.12958
https://www.ncbi.nlm.nih.gov/pubmed/25488623 (öffnet neues Fenster)